Avaliação da atividade citotóxica e antitumoral de novos derivados de quinazolina em modelo de adenocarcinoma mamário
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Breast cancer is an uncontrolled growth of epithelial cells originating from the
mammary ducts or lobules. The National Cancer Institute estimates that breast cancer
is the most common cancer in women, with 73,610 new cases of breast cancer
registered each year for the three-year period 2023-2025, corresponding to a rate of
41.89 cases per 100,000 women. Unfortunately, many traditional therapies for breast
cancer treatment have limitations that diminish their effectiveness, including problems
related to adverse reactions and the development of drug resistance. Quinazoline
derivatives have demonstrated efficacy against various types of cancer, including
drug-resistant forms, thus representing a rich source for the development of new
chemotherapeutic agents for the treatment of breast cancer. This study evaluated the
cytotoxic potential of new quinazolines through in vitro cytotoxicity assays and in vivo
efficacy studies. An in vitro screening revealed that two new quinazolines, named
KDY3 and KDY23, showed promising activity in several breast cancer cell lines (4T1,
MDA-MB-231, MCF-7), exhibiting IC50 values in the range of 5.72 to 14.74 μM.
Therefore, both substances were selected for in vivo studies. The substances were
tested in a syngeneic breast cancer model induced by orthotopic inoculation of murine
4T1 breast cancer cells into BALB/c mice. The mice were divided into control and
treated groups. In the treatment groups, animals were treated with KDY3 (15 or 30
mg/kg/week, with an initial dose of 100 or 200 mg/kg), and KDY23 (15 or 30 mg/kg
every three days, with an initial dose of 100 or 200 mg/kg) or doxorubicin (5
mg/kg/week) as a standard control. In the 30 mg/kg/week dosing regimen with an initial
dose of 200 mg/kg, KDY3 significantly reduced tumor volume (338.61 ± 97.53 mm³
vs. 545.49 ± 151.56 mm³ in untreated control groups; p = 0.024) without lethal effects
and without significant reduction in animal weight. Animals in the doxorubicin group,
however, experienced significant weight reduction. This may suggest that
experimental treatment with KDY3 may have demonstrated lower toxicity compared to
the control treatment with doxorubicin. Cytokine dosage assays revealed that KDY3,
at a dosage regimen of 30 mg/kg/week with an initial dose of 200 mg/kg, showed an
immunomodulatory effect, as it increased the level of IFN-γ in intratumoral tissue. In
conclusion, the quinazoline KDY3 can be considered a promising drug candidate for
the treatment of breast cancer. KDY23, on the other hand, showed good results in
vitro, but dosage adjustments are needed to reduce its toxicity.
Description
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

